OC 316Homo sapiens (Human)Cancer cell line
Also known as: OC316, OC-316
🤖 AI SummaryBased on 6 publications
Quick Overview
Ovarian cancer cell line with genomic instability and potential for drug sensitivity studies.
Detailed Summary
OC 316 is an ovarian cancer cell line derived from a human tumor, characterized by genomic instability and specific mutations that may influence its response to therapeutic agents. This cell line has been analyzed in multiple studies focusing on chromosomal alterations and their implications in cancer progression. Research indicates that OC 316 exhibits features associated with high-grade serous ovarian cancer, making it a relevant model for studying this aggressive cancer subtype. The cell line's genetic profile, including mutations in key cancer-related genes, provides insights into the molecular mechanisms underlying ovarian cancer development and treatment resistance. Additionally, OC 316 has been used in studies evaluating the efficacy of targeted therapies and drug sensitivity, contributing to the understanding of potential therapeutic strategies for ovarian cancer patients.
Research Applications
Genomic instability studiesDrug sensitivity profilingCancer progression modelingTargeted therapy evaluation
Key Characteristics
Genomic instabilityMutations in cancer-related genesHigh-grade serous ovarian cancer modelPotential for drug response studies
Generated on 6/17/2025
Basic Information
| Database ID | CVCL_1618 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Ascites[UBERON:UBERON_0007795] |
Donor Information
| Age | 60 |
|---|---|
| Age Category | Adult |
| Sex | Female |
Disease Information
| Disease | Ovarian serous adenocarcinoma |
|---|---|
| Lineage | Ovary/Fallopian Tube |
| Subtype | Serous Ovarian Cancer |
| OncoTree Code | SOC |
DepMap Information
| Source Type | ICLC |
|---|---|
| Source ID | ACH-001145_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Arg273His (c.818G>A) | Homozygous | - | Unknown, PubMed=16264262 |
| MutationSimple | RRAS | p.Pro26fs (c.74delC) | Heterozygous | - | Unknown |
| MutationSimple | B2M | p.Leu15Phefs*41 (c.43_44delCT) | Heterozygous | Total loss of HLA class 1 expression | from parent cell line LoVo |
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines
Loading gene expression data...
Publications
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
Evaluating cell lines as tumour models by comparison of genomic profiles.
Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.
Nat. Commun. 4:2126.1-2126.10(2013).
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Mills G.B., Hennessy B.T.
Mol. Oncol. 7:567-579(2013).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.
Edwards P.A.W., Caldas C.
Carcinogenesis 26:923-930(2005).